Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.

Hope S RugoPeter SchmidSara M TolaneyFlorence DalencFrederic MarméLing ShiWendy VerretAnuj ShahMahdi GharaibehAditya BardiaJavier Cortes

Published in: The oncologist (2024)

SG was associated with an HRQoL benefit in most symptoms and functioning, compared with TPC. This supports the favorable profile of SG as a treatment option for patients with pretreated HR+/HER2- mBC.

Keyphrases

phase iii
metastatic breast cancer
open label
clinical trial
phase ii
double blind
placebo controlled
study protocol
depressive symptoms